An energetic low-dose naltrexone (LDN) field.
What is LDN?
- Naltrexone, an opioid antagonist initially approved for managing alcohol and opioid dependence, is utilized in low doses (LDN) for immune modulation.
- LDN is recognized for its potential to modulate the immune system, with accumulating evidence suggesting its efficacy in reducing inflammatory autoimmune processes.
What is Being Treated with LDN?
- LDN has been explored in various conditions, including autoimmune diseases (e.g., Crohn’s disease, multiple sclerosis), neurological disorders (e.g., Parkinson’s disease, autism), cancers (e.g., melanoma, prostate cancer), infectious diseases (e.g., HIV/AIDS, hepatitis C), gastrointestinal disorders, and pain syndromes.
Benefits:
- LDN’s mechanism involves blocking opioid receptors, leading to a rebound effect of increased endorphin production, which can positively impact immune cells.
- Clinical studies and patient-reported data suggest LDN may downregulate inflammatory cytokines, reduce inflammation and oxidative stress, facilitate tissue repair, restore immune balance, and inhibit tumor growth.
- LDN has shown potential benefits in various conditions, including improved quality of life, disease prevention, and immune monitoring.
Overall, LDN offers a promising approach to managing a wide range of medical conditions with potential disease-modifying effects and improved patient outcomes.
There are a number of conditions where LDN could benefit based on clinical studies and
patient data:
Summary
PUBLISHED CLINICAL STUDIES
• Crohn’s Diseases
• Multiple Sclerosis
• Fibromyalgia
• HIV/AIDS
• Melanoma,
• Prostate Cancer
• Cervical Cancer
• Autism
• Ulcerative Colitis
• Hepatoblastoma
• Chemo Resistant Advanced
Carcinoma
• Metastatic Breast
• Glioma Patients
• Gulf War Syndrome
• Complex Regional Pain Syndrome
• Pruritus in Systemic Sclerosis
• Gastrointestinal Disorders
• Irritable Bowel Syndrome
PATIENT-REPORTED
• Malaria
• Epstein-Barr Syndrome
• Hepatitis C
• Lung Cancer
• Rheumatoid Arthritis
• Bladder Cancer
• Systemic Lupus Erythematosus
• Breast Cancer
• Parkinson’s Disease
• Lymphoma (Hodgkin’s and Non
• Wound Healing
• Hodgkin’s) Colon & Rectal Cancer
• Malignant Melanoma
• Uterine Cancer
• Glioblastoma
• Throat Cancer
• Liver Cancer
• Neuroblastoma
• Multiple Myeloma
• Renal Cell Carcinoma
• Ovarian Cancer
For a list of current ongoing LDN studies, please go to the following website:
https://clinicaltrials.gov/ct2/results?term=low+dose+naltrexone&Search=Search